FOSUN HEALTH Logo

Endometrial Cancer Prevention

catalogue

Endometrial Cancer Prevention

Endometrial Cancer Prevention

Endometrial cancer prevention has an unusual shape: the commonest gynaecological cancer has no screening test for women at average risk, yet offers several effective ways to lower risk — weight control and the contraceptive pill for everyone, and structured surveillance for the small group with Lynch syndrome.

Why there is no screening test

Cervical screening works because the cervix sits at the top of the vagina, where a swab samples the exact cells at risk. The endometrium has no such geometry: cells shed from the lining are not reliably captured by a cervical sample, ultrasound thickness varies through the cycle, and no blood test marks the precancer. Organised screening of healthy women would produce procedures and false alarms more than it would produce earlier diagnoses — which is why no major guideline recommends screening at average risk.

The disease buys back the gap another way: it announces itself. The same lining that turns malignant bleeds when it breaks down, and bleeding after menopause is a symptom no one can ignore. The result is that most endometrial cancers are found early despite the absence of screening — the symptom is the screening, provided it is acted on. The safety net, in other words, is a population that knows the rule: any bleeding after menopause, and persistent irregular bleeding before it, gets an ultrasound and a biopsy.

Surveillance for Lynch syndrome

For the small group at hereditary risk — Lynch syndrome carriers — the calculus changes entirely, and screening becomes standard. The programme:

  • Annual surveillance from age 35 — hysteroscopy with biopsy of the lining, or ultrasound plus biopsy, repeated every year; the interval is short because Lynch tumours grow fast.
  • Colonoscopy on the same schedule — endometrial and colon risk travel together, and one programme manages both.
  • Risk-reducing hysterectomy after childbearing — removal of uterus, tubes and ovaries, discussed case by case with a genetics team; it removes the risk at its source and is a genuine, commonly chosen option.

The entry point is testing, and it is easier than it used to be: every endometrial cancer diagnosed under 60, and every case with colon cancer in the close family, is a prompt for mismatch-repair testing of the tumour — the same test that guides immunotherapy. Where it is abnormal, a blood test confirms Lynch syndrome, and the surveillance plan extends to siblings and children. One test, one decision, a whole family's plan.

Weight and activity

Because postmenopausal fat tissue is the main estrogen factory, weight is the strongest modifiable lever on this disease — and the lever moves in the right direction. Weight loss after menopause lowers circulating estrogen measurably; population data show the risk of endometrial cancer falling with each sustained reduction in weight, more clearly than for almost any other cancer. Physical activity adds an independent effect on top of weight, through insulin and inflammation pathways.

Framed honestly: no one loses weight because a statistic asked them to, and most women with obesity never develop this cancer. The leverage point is different — for a woman already weighing the effort, this disease is one of the clearest cases where the effort maps onto the risk, and the same change lowers the risk of several other cancers at once. The realistic goal is direction, not perfection: sustained reduction, however modest, moves the pathway.

The pill, the IUD and pregnancy

Three protective factors share one mechanism — they all restore the progesterone counterweight that unopposed estrogen lacks:

  • The combined contraceptive pill — years of use lower endometrial cancer risk substantially, with protection persisting for years after stopping. It is one of the best-established protective effects in gynaecology.
  • The progestin-releasing intrauterine device — delivers the counterweight directly to the lining; used both for contraception and as part of hyperplasia treatment, and associated with lower risk.
  • Pregnancy — months of continuous high progesterone, followed by months of lactation, give the lining its longest sustained rest; never having been pregnant is a risk factor precisely because that rest never arrives.

None of these is a free-floating recommendation — each is a decision inside a woman's own contraception and family planning, weighed against other considerations. The point for this page is narrower: where a woman is choosing anyway, the endometrial effect is a real, evidence-based item on that list.

What prevention cannot do

An honest page states its limits. Weight, the pill and pregnancy lower risk; they do not reduce it to zero — endometrial cancer also occurs in women with none of the risk factors, in women at normal weight, and in Lynch carriers who have done everything asked of them. Nor does protection extend to the aggressive types: serous and clear-cell carcinomas arise outside the estrogen pathway, and no lifestyle measure reaches them.

And the surveillance that protects Lynch carriers is not portable: annual hysteroscopy for women at average risk is not recommended, because the procedure itself carries risks and the yield is low. What travels from the high-risk programme to everyone is the principle it runs on — act on bleeding, not on schedules. The woman who reports postmenopausal bleeding the week it starts has, in practice, done what screening would have done for her.

A practical plan

Condensed to what a reader can act on this month:

  • Everyone: know the rule — any bleeding after menopause, and persistent irregular bleeding before it, gets an ultrasound and a biopsy. Keep the weight direction honest. If choosing contraception anyway, weigh the pill and the progestin IUD with their protective effect in mind.
  • If tamoxifen or estrogen-only therapy is part of your care: no extra screening is needed — but report bleeding without exception and without delay.
  • If colon cancer appeared young in the family, or endometrial cancer across generations: ask for mismatch-repair testing of any relevant tumour and a genetics referral. The test is one blood draw and the plan it unlocks covers a family.
  • If Lynch syndrome is already confirmed: annual lining surveillance from 35, colonoscopy on schedule, and a discussed decision about risk-reducing hysterectomy once childbearing is complete.

For readers with a suspicious symptom right now rather than a plan: the symptoms page sets out which patterns warrant same-month assessment.

Frequently Asked Questions

Should I ask for a screening test anyway, for peace of mind?

A symptom-triggered assessment is always available — that is the correct response to abnormal bleeding, at any age. But routine screening of an asymptomatic lining at average risk is not recommended, and requesting an ultrasound for reassurance alone tends to buy false certainty: a thin lining one month does not exclude a lesion the next, and the test would need repeating indefinitely. The evidence-based reassurance is different: know the bleeding rule, act on it within days rather than months, and if Lynch syndrome runs in the family, get tested — that is the group where scheduled surveillance is real.

How do I find out if I have Lynch syndrome?

The modern route runs through the tumour, when there is one: every endometrial cancer is tested for mismatch-repair proteins as standard, and an abnormal result triggers confirmatory blood testing for Lynch syndrome. Without a cancer diagnosis, the route is a genetics clinic: a family history of colon cancer diagnosed young, or endometrial cancer across generations, qualifies for assessment, and a blood panel can test for the condition directly. Either way the result is a family matter — it changes surveillance for siblings and children, not only for the person tested.

Can weight loss really lower the risk after menopause?

Yes — more clearly than for most cancers. Fat tissue is the main estrogen source after menopause, and sustained weight reduction measurably lowers circulating estrogen and, in population data, the risk of endometrial cancer falls with it. The effect is dose-dependent and does not require reaching an ideal weight: direction and maintenance matter more than magnitude. Combined with the independent effect of physical activity, weight is the one lever on this disease's risk list that a patient controls outright.

I have finished my family and carry Lynch syndrome — is preventive surgery reasonable?

It is a standard, guideline-endorsed option and the one that removes the risk at its source: hysterectomy with removal of tubes and ovaries, discussed with a genetics and gynaecological oncology team, usually once childbearing is complete. It is also a real operation with a real recovery, and it brings on menopause directly — the timing, the approach and the hormone-therapy questions afterwards are individual decisions, not defaults. What matters is that the option is on the table and discussed rather than discovered late; carriers who want it are not being extreme.

Map your situation against guidance

Whether surveillance, testing or risk-reducing surgery is appropriate depends on your family history and records. Send what you have, and our gynaecological oncology team will map your situation against current guidance — a written reply within 48 hours.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*